Cargando…
Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
Lenalidomide is a lead therapeutic in multiple myeloma and deletion 5q myelodysplastic syndromes and shows promising activities in other hematologic malignancies. This article presents a comprehensive review of the clinical pharmacokinetics and pharmacodynamics of lenalidomide. Oral lenalidomide is...
Autores principales: | Chen, Nianhang, Zhou, Simon, Palmisano, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5247551/ https://www.ncbi.nlm.nih.gov/pubmed/27351179 http://dx.doi.org/10.1007/s40262-016-0432-1 |
Ejemplares similares
-
Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel
por: Chen, Nianhang, et al.
Publicado: (2014) -
Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted in Healthy Men
por: Chen, Nianhang, et al.
Publicado: (2013) -
Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects
por: Chen, Nianhang, et al.
Publicado: (2011) -
No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers
por: Chen, Nianhang., et al.
Publicado: (2014) -
Erratum to: No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers
por: Chen, Nianhang, et al.
Publicado: (2014)